News Release

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

January 17, 2014

Approval of Fine Granules of Topina®, an Antiepileptic Agent

Tokyo, Japan, January 17, 2014 --- Kyowa Hakko Kirin Co., Ltd. (Tokyo; 4151 President and CEO: Nobuo Hanai; "Kyowa Hakko Kirin") announced today that it has received approval for Topina® fine granules (Generic name: topiramate) as a new formulation in Japan.

Since the launch in September 2007, Topina® Tablets have been used in adult epileptic patients for the treatment of partial onset seizures inadequately controlled with other antiepileptic drugs. In November 2013, the drug was approved an additional dosage and administration for the treatment in pediatric epileptic patients aged two or older (as an adjunctive therapy with other antiepileptic drugs).
This newly approved formulation, Topina® fine granules, would be more appropriate for administration in pediatric and elderly patients with epilepsy and improve the drug adherence.

Kyowa Hakko Kirin has four strategic categories including the central nervous system (CNS) area, and is endeavoring to contribute to the treatment of epilepsy through the further development of antiepileptic agents and the provision of related information.


About four categories
These are the following four disease areas: Nephrology, Oncology, Immunology & Allergy, and Central Nervous System, as presented in Kyowa Hakko Kirin's FY 2013-2015 medium-term business plan.


Contact:

Kyowa Hakko Kirin
Media Contact:
+81-3-3282-1903
or
Investors:
+81-3-3282-0009



To Page Top